NDAORALTABLET
Approved
Jan 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Clinical Trials (5)
Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
Started Jul 2026
Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity
Started Jun 2026
3,000 enrolled
Obesity & Overweight
AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
Started May 2026
1,000 enrolled
ObesityOverweightDiabetes Mellitus, Type 2
Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes
Started Mar 2026
Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
Started Feb 2026
600 enrolled
Diabetes Mellitus, Type 2